半球后注射曲安奈德治疗甲状腺相关眼病  

Treatment of thyroid associated ophalmopathy by semiretrobulbar injection of triamcinolone acetonide

作　　者：王崇玉[1] 

机构地区：[1]南京爱尔眼科医院,中国江苏省南京市210006

出　　处：《国际眼科杂志》2013年第2期398-399,共2页International Eye Science

摘　　要：目的:评价半球后注射曲安奈德(triamcinolone acetonide,TA)治疗甲状腺相关眼病(thyroid associated ophthalmopathy,TAO)的临床效果。方法:对46例84眼甲状腺相关眼病患者以TA40mg加20g/L利多卡因0.5mL行眼部半球后注射,每3wk1次,连续4次为1疗程,1,3,6mo随访观察,记录眼部症状、体征情况。结果:患者43例自觉症状明显改善,眼球回退率83.6%,眼裂宽度缩小率85.2%,双眼视力改善率80.9%,眼球运动障碍、复视、斜视改善率80.5%。结论:半球后注射TA治疗甲状腺相关眼病效果明显,不良反应小,安全可靠。AIM： To evaluate clinical effects of semiretrobulbar injection of triamcinolone acetonide （TA） for the treatment of thyroid associated ophalmopathy. METHODS： Totally 84 eyes of 46 cases with thyroid associated ophalmopathy were treated with semiretrobulbar injection of TA （40mg） with 20g/L Lidocaine （0.5 mL） for each eye once every three weeks for four times during one course of treatment. Then symptoms and signs of the patients were observed after 1 month, 3 months, 6 mouths. RESULTS： Symptoms of 43 cases were improved significantly. In all cases, eyeball recession rate was 83.6%, the palpebral fissure width reduction was 85.2%, visual acuity improvement was 80.9%, eye movement, strabismus, and diplopia improvement was 80. 5%, compared to those before the treatment. CONCLUSION： The treatment of semiretrobulbar injection of TA for thyroid associated ophalmopathy is safe. effective and mild in side effect.

关 键 词：曲安奈德 甲状腺相关眼病 半球后注射 

分 类 号：R771.3[医药卫生—眼科]